Center Book Partners LP Ascendis Pharma A/S Transaction History

Center Book Partners LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$121.07 - $153.67 $1.32 Million - $1.68 Million	10,905 New	10,905 $1.49 Million
Q4 2023 Feb 13, 2024	SELL	$86.1 - $127.36 $371,693 - $549,813	-4,317 Reduced 45.33%	5,207 $655,000
Q3 2023 Nov 13, 2023	SELL	$86.5 - $103.97 $1.18 Million - $1.42 Million	-13,615 Reduced 58.84%	9,524 $891,000
Q2 2023 Aug 14, 2023	BUY	$69.96 - $97.84 $1.18 Million - $1.65 Million	16,864 Added 268.75%	23,139 $2.07 Million
Q1 2023 May 15, 2023	SELL	$104.9 - $126.78 $305,783 - $369,563	-2,915 Reduced 31.72%	6,275 $672,000
Q4 2022 Feb 13, 2023	BUY	$99.42 - $131.97 $659,751 - $875,752	6,636 Added 259.83%	9,190 $1.12 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $130,162 - $170,746	-1,549 Reduced 37.75%	2,554 $264,000
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $320,362 - $482,553	4,103 New	4,103 $381,000

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Center Book Partners LP, based on Form 13F filings with the SEC.

Stay updated on Center Book Partners LP with notifications on news.